

The background features a dark blue gradient with a starry space pattern. Overlaid on this are several circular gauges and arcs. One large gauge on the left has numerical markings from 140 to 260. Other gauges are smaller and partially visible. The overall aesthetic is technical and scientific.

THOR UPDATES

PHILIP C. SPINELLA, MD, FCCM
PROFESSOR, DEPARTMENTS OF SURGERY AND CRITICAL CARE MEDICINE
CO-DIRECTOR, TRAUMA AND TRANSFUSION MEDICINE CENTER
DEPARTMENT OF SURGERY
ASSOC. MEDICAL DIRECTOR, CENTER FOR MILITARY MEDICINE RESEARCH
UNIVERSITY OF PITTSBURGH


THOR EXECUTIVE COMMITTEE

- Spinella, Co-Director
- Strandenes, Co Director
- Glassberg, Senior Advisor
- Cap, Senior Advisor

MEMBERSHIP

- Invitation to attend
 - Expand membership with right membership
 - Balance of expertise and change agents
- Attendance = membership
- No dues (for now)

WEBSITE UPGRADE



WORKING GROUPS

- Agenda
 - Oct 10-Nov 7 accepting submissions
- Publications
- Virtual Education Series
- Social Media
- Training Course

SUPPLEMENT

THE JOURNAL OF AABB transfusion.org

TRANSFUSION

Vol. 64, No. S2,
May 2024

LIFE YEARS GAINED DUE TO RHD-POSITIVE LTOWB TRANSFUSION EXCEEDS LIFE YEARS LOST TO FATAL AND SEVERE HDFN AT >0.1% MORTALITY RELATIVE REDUCTION (MRR)

Age of RhD-negative FCP when exposed to RhD positive LTOWB in trauma	MRR 0.1%	MRR 0.5%	MRR 1.0%	MRR 5.0%	MRR 15.0%	MRR 25.0%
0	0.5	0.5	0.5	3.5	11.5	18.5
4	0.5	0.5	0.5	3.5	11.5	18.5
8	0.5	0.5	0.5	3.5	11.5	18.5
12	0.5	0.5	0.5	3.5	11.5	18.5
16	0.5	0.5	0.5	3.5	11.5	18.5
20	0.5	0.5	0.5	3.5	11.5	18.5
24	0.5	0.5	0.5	3.5	11.5	18.5
28	0.5	0.5	0.5	3.5	11.5	18.5
32	0.5	0.5	0.5	3.5	11.5	18.5
36	0.5	0.5	0.5	3.5	11.5	18.5
40	0.5	0.5	0.5	3.5	11.5	18.5
44	0.5	0.5	0.5	3.5	11.5	18.5
48	0.5	0.5	0.5	3.5	11.5	18.5

A Supplement to TRANSFUSION
The THOR Network 2024 Remote Damage Control Resuscitation Supplement

Guest Editors:
Mark H. Yazer, MD
Sarah A. Watts, MRCVS
Christine M. Leeper, MD MS

THOR-AABB JOINT GROUP

- Review of pro and con of using platelet sparing filter for LTOWB
- Conclusion
 - For clinical programs that use LTOWB for life threatening hemorrhage, the data do not support requiring LR for LTOWB to treat patients with life threatening hemorrhage.
 - The leukoreduction of LTOWB for these patients could be considered optional unless its use is mandated by local or national regulations.
- In Press, Transfusion

THOR NETWORK FOUNDATION

- Fundraising efforts to support projects
 - Training/Education
 - Research
 - Advocacy
- First grant from Johnson and Johnson Foundation

THOR RESEARCH INSTITUTE

- Director, Andre Cap
- Design and execute laboratory and clinical research
 - For Industry
 - With Investigators

THOR RESEARCH INSTITUTE

- Previous/Current projects
 - DoD/Pitt University
 - HDFN conference
 - Cerus
 - Lab project and clinical trial
 - MEQU
 - Lab project design
 - Blood Works
 - Clinical trial

RECOMMENDATIONS FOR TREATMENT OF SEVERE BLEEDING IN WOMEN AND PREVENTION/TREATMENT OF HDFN

- Nov 19 and 20 , panel of 45 experts
- Johns Hopkins EBM Center
 - Formal literature review and grading
- Recommendations in areas of
 - Trauma/Transfusion Medicine
 - Hematology
 - Obstetrics/Maternal Fetal Medicine
 - Neonatology/Pediatrics
- Collaboration with Allo-Hope Foundation
- Funded by DoD/CCCRP



A Public Discussion of Evidence Based Guidelines for
**Emergency Transfusion in Females With
Childbearing Potential:** Mitigating the Risks
of Hemolytic Disease of the Fetus and Newborn



More information at <https://bit.ly/3W85nkB>

THOR ON THE ROAD

- Rome, Italy: Oct 2024
- Madrid, Spain; Nov 2024
- Warsaw, Poland; Nov 2024
- Perth, Australia; Nov 2025

FUTURE THOR MEETINGS

- Solstrand Spa, May 18-21, 2025
- 2026 options in early June
 - Dublin
- Goal is to rotate between Norway, US and Ireland.
 - Same location each time

THOR STAFF GROWING

- Conference Director
 - Dan Martin
 - Janna (Norway)
- Relations Director
 - Kara O'Connor
- Contracting Officer
 - Blythe Burkhardt
- Financial Officer
 - Sue Reyer